Article review : RETAIN Bladder ? Can we get away with only chemotherapy in MIBC
Reference:
Geynisman DM, et al. Phase II Trial of Risk-Enabled Therapy
After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). J
Clin Oncol. 2025;43(9):1113-1122. doi:10.1200/JCO-24-01214
RETAIN 1 represents thoughtful, rigorous science addressing
a real clinical problem: how to balance oncologic efficacy with quality-of-life
preservation in MIBC. For appropriately selected patients—those with favorable
biology (DNA repair mutations), excellent chemotherapy response, and personal
commitment to surveillance—deferring cystectomy appears oncologically safe.
However, this is not a one-size-fits-all solution. Success
requires careful patient selection, frank discussions about recurrence risk,
infrastructure to support intensive surveillance, and readiness to proceed with
salvage cystectomy if recurrence is detected.
For practicing clinicians, RETAIN 1 should inform enhanced
conversations with MIBC patients about options. For healthcare systems, it
suggests the value of infrastructure investments in precision oncology and
surveillance capacity. For researchers, it highlights the need for definitive
phase III evidence before reshaping standard of care.
The future of MIBC management may indeed involve more
bladder preservation—but that future is built on the foundation of careful
patient selection, high-quality surveillance, and honest communication about
both benefits and risks.
The RETAIN 1 Trial: A Game-Changer for Bladder Cancer? A
Clinician's Guide
The Big Picture: What Is RETAIN 1 and Why Should You Care?
For decades, the standard treatment for muscle-invasive
bladder cancer (MIBC) has been straightforward but brutal: chemotherapy
followed by removal of the entire bladder. The surgery—called radical
cystectomy—works, but it extracts a heavy price. Patients face permanent
urinary diversion (a surgically created stoma), sexual dysfunction, metabolic
problems, and significant loss of quality of life.
The RETAIN 1 trial, published in December 2024 in the Journal
of Clinical Oncology, asks a radical question: Do all patients really
need that surgery?
The answer, for a carefully selected subset of patients,
appears to be no.
Understanding the Standard Treatment Approach
Before diving into RETAIN 1, it's worth understanding why
bladder removal has become the default treatment for MIBC.
The Current Gold Standard:
- Cisplatin-based
chemotherapy (called neoadjuvant chemotherapy) given before surgery
- Radical
cystectomy (complete bladder removal) with pelvic lymph node dissection
- Creation
of a permanent urinary diversion—usually an ileal conduit (a surgically
fashioned opening on the abdomen where urine drains into a bag worn
externally)
This approach works well from an oncology standpoint.
Roughly 70-75% of patients remain cancer-free at 2 years. But the human cost is
substantial. Many patients develop urinary incontinence, chronic kidney
disease, sexual dysfunction, and psychological distress related to the stoma.
Enter RETAIN 1: A Different Philosophy
The RETAIN 1 research team—led by Daniel Geynisman and
colleagues at major US academic centers—asked: What if we could identify
which patients respond so well to chemotherapy that they might safely skip the
surgery?
Their approach was elegant:
- Give
all patients chemotherapy (accelerated MVAC—a potent regimen)
- Test
their tumors for specific genetic mutations related to DNA repair
- Assess
response meticulously with repeat imaging and cystoscopy
- For
complete responders with DNA repair mutations, offer active
surveillance (close monitoring) instead of immediate cystectomy
- Salvage
with cystectomy if recurrence is detected
Who Gets to Skip Surgery? The Biomarker Question
This is the crucial gatekeeping mechanism. RETAIN 1 didn't
offer surveillance to all MIBC patients—only to those with specific genetic
characteristics.
The DNA Repair Gene Mutations:
Researchers sequenced tumors for mutations in four genes
involved in DNA repair:
- ATM
- ERCC2
- FANCC
- RB1
Why these genes? Because patients whose tumors carry these
mutations tend to respond exceptionally well to chemotherapy. Their cancer
cells are already "broken" at the DNA repair level, making them more
vulnerable to chemotherapy's DNA-damaging effects.
The Numbers:
- 47%
of enrolled patients had at least one qualifying mutation
- But
only 36% of total enrollment (25 patients) actually started active
surveillance
- Why
the gap? Patients without mutations were excluded, and some patients
didn't achieve complete response to chemotherapy
The Key Point: This biomarker-driven approach is
precision medicine in action. It's not "one size fits all"—it's
personalized selection based on tumor biology.
The Trial Results: What Actually Happened?
The RETAIN 1 team followed 70 patients across four major
academic medical centers for a median of 40 months. Here's what they found:
The Primary Outcome:
- 2-year
metastasis-free survival: 72.9% (95% CI lower bound 62.8%)
- This
exceeded the trial's pre-specified threshold of 64%, meeting the
non-inferiority goal
What Does This Mean in Plain Language?
At 2 years post-chemotherapy, roughly 7 out of 10 patients
who deferred cystectomy and underwent active surveillance had not developed
distant metastases. This is comparable to the 70-75% outcomes seen with
standard cystectomy, but without removing the bladder.
Additional Outcomes:
- 2-year
overall survival: 84.3%—most patients were alive at this time point
- Among
the 25 patients in active surveillance: 68% experienced recurrent disease
at the surgical site (in the bladder), but 48% maintained metastasis-free
survival with their bladder intact
The Reality Check: Not Everyone Avoided Surgery
Here's where the rubber meets the road: 68% of
surveillance patients needed further treatment because their cancer came
back locally (in the bladder).
This is not a failure—it's the expected recurrence pattern
for MIBC. What matters is what happened next:
- Some
patients underwent additional chemotherapy
- Others
had repeat transurethral resection of tumor (TURBT—a less invasive
procedure)
- A
subset ultimately underwent cystectomy after recurrence was detected
- Critically, recurrence
was detected early through surveillance, allowing salvage therapy before
metastatic spread
The Key Insight: Active surveillance isn't a cure; it's
a bridge strategy. It buys time with a functioning bladder while remaining
vigilant for recurrence. For some patients, that trade-off is worth it. For
others, immediate cystectomy is the right choice.
Who Benefits From This Approach?
RETAIN 1 suggests active surveillance is worth considering
for patients meeting all these criteria:
✅ Clinical Stage: cT2-T3N0M0
(muscle-invasive, node-negative)
✅ Fitness: Cisplatin-eligible
(adequate kidney function, cardiac fitness)
✅ Tumor Biology: Harbors
DNA repair mutations (ATM, ERCC2, FANCC, or RB1)
✅ Treatment Response: Achieves
complete response to chemotherapy (no residual cancer on repeat cystoscopy and
imaging)
✅ Patient Preference: Values
bladder preservation and commits to intensive surveillance
✅ Realistic Expectations: Understands
recurrence risk and accepts possibility of delayed cystectomy
The Elephant in the Room: Limitations
RETAIN 1 is important science, but it's not the final word.
Here are the key limitations:
1. Phase II, Not Phase III
This is proof-of-concept, not a definitive practice standard. A phase III
randomized trial comparing active surveillance versus immediate cystectomy
would provide stronger evidence.
2. Small Sample Size
Only 70 total patients, with just 25 in active surveillance. Small numbers mean
less precision and greater uncertainty, particularly for estimating long-term
outcomes.
3. Short Follow-Up
Two years is appropriate for detecting metastases but limited for assessing
truly long-term recurrence patterns or late complications of delayed
cystectomy.
4. Narrow Population
- Only
36% of enrolled patients qualified for active surveillance
- Highly
selective: cisplatin-eligible, biomarker-positive, complete responders
- 92%
white, 74% male—doesn't represent diversity in bladder cancer populations
- Excludes
the ~30-40% of MIBC patients too unfit for cisplatin
5. Missing Quality-of-Life Data
The trial didn't systematically measure patient-reported outcomes—a critical
gap given that quality-of-life preservation is the central motivation for
bladder preservation.
6. No Cost-Effectiveness Analysis
From a healthcare system perspective, is surveillance cheaper than upfront
cystectomy, considering diagnostic workup costs?
What Does "Complete Response" Actually Mean?
This is worth unpacking because it's central to RETAIN 1's
logic.
After chemotherapy, the trial team performed rigorous
reassessment:
- Repeat
cystoscopy (examining the bladder with a camera)
- Urine
cytology (looking for cancer cells in urine)
- Cross-sectional
imaging (CT or MRI to assess for lymph node or distant disease)
"Complete response" meant no visible tumor on
cystoscopy, no cancer cells in urine, and no imaging evidence of advanced
disease.
The Assumption: If chemotherapy eliminated all visible
tumor and the tumor had DNA repair mutations (suggesting chemotherapy
sensitivity), the probability of occult (hidden) metastatic disease was
acceptably low.
The Reality Check: 68% of these "complete
responders" later developed recurrence, showing that complete response,
while favorable, is not synonymous with cure.
How Does This Compare to Other Bladder-Preservation
Approaches?
It's important to note that cystectomy isn't the only
alternative to simple surveillance. There's another bladder-preserving strategy
called trimodal therapy:
Trimodal Therapy = Maximal TURBT + Chemotherapy +
Radiation
This approach aims to cure MIBC while preserving the bladder
through coordinated chemotherapy and targeted radiation. Published trials show
roughly 70-80% long-term bladder preservation rates with oncologic outcomes
comparable to cystectomy.
How Does RETAIN 1 Compare?
- RETAIN
1: Chemotherapy + surveillance (72.9% 2-year MFS)
- Trimodal
therapy: Chemotherapy + radiation + surveillance (70-80% 5-year bladder
preservation)
RETAIN 1 doesn't directly compare to trimodal therapy, so
the relative merits remain unclear. Some patients might be better served by
trimodal therapy's upfront radiation (which sterilizes remaining disease),
while others might prefer RETAIN 1's chemotherapy-only approach if surveillance
capacity exists.
The Quality-of-Life Case for Bladder Preservation
This is where RETAIN 1's significance becomes deeply
personal.
Radical cystectomy requires permanent urinary diversion,
usually an ileal conduit. Picture yourself:
- Wearing
an external stoma pouching system 24/7
- Managing
potential skin irritation and odor
- Experiencing
40-50% rates of sexual dysfunction post-surgery
- Dealing
with metabolic complications (kidney stones, chronic kidney disease)
- Experiencing
psychological distress related to altered body image
For patients who could avoid this through successful
surveillance, the quality-of-life benefit is substantial.
RETAIN 1 preserves native bladder function in 32% of
surveillance patients long-term. Even in the 68% who eventually need
intervention, they've gained months or years of normal urinary function—a
non-trivial benefit.
Critical Appraisal for the Practicing Clinician
Strengths of the Evidence:
- ✅
Prospective, multi-center design with standardized protocols
- ✅
Biomarker-driven selection—incorporates precision medicine principles
- ✅
Rigorous restaging methodology—minimizes risk of missing residual disease
- ✅
Oncologic outcomes comparable to cystectomy
- ✅
Addresses real patient concern: quality of life
Weaknesses of the Evidence:
- ❌
Phase II design—proof-of-concept, not definitive
- ❌
No control group—reliance on historical cystectomy benchmarks
- ❌
Small sample size, particularly for surveillance cohort (n=25)
- ❌
Limited follow-up (2 years); late recurrence patterns unknown
- ❌
Narrow population—36% of MIBC patients qualify
- ❌
No quality-of-life or cost-effectiveness data
- ❌
Non-diverse population (92% white, 74% male)
Is RETAIN 1 Practice-Changing? The Honest Answer
For Specialized Academic Centers: Possibly yes. At
high-volume, multidisciplinary institutions with genomic sequencing, MDT
coordination, and surveillance infrastructure, RETAIN 1 provides justification
for offering surveillance as an option within shared decision-making for appropriate
candidates.
For Community Practice: Not yet. The biomarker-enriched
selection, infrastructure requirements, and small trial size mean RETAIN 1 is
better viewed as hypothesis-generating rather than practice-transforming.
For Definitive Practice Change: We'd need a phase III
randomized trial comparing active surveillance versus cystectomy in
biomarker-selected populations, with long-term follow-up (5+ years) and
integrated quality-of-life outcomes.
Implications for UK NHS Practice
The UK healthcare system could benefit from RETAIN 1's
insights, but implementation requires careful consideration:
Current Reality:
- Most
NHS cancer networks lack routine genomic sequencing for MIBC
- Urology
services are stretched; intensive surveillance requires protected capacity
- Multidisciplinary
team availability varies significantly across regions
Potential Implementation Pathway:
- Pilot
programs in designated high-volume cancer centers (London,
Manchester, Birmingham, etc.)
- Coordinated
genomic testing through existing cancer networks
- Standardized
surveillance protocols defining cystoscopy intervals, imaging
modalities, recurrence thresholds
- Patient
selection restricted to cisplatin-eligible, complete responders with
biomarkers
- Outcomes
registry comparing surveillance versus cystectomy cohorts in UK
population
- Integration into
existing NHS guidelines after pilot validation
Cost Implications:
- Upfront
savings: Avoid £15,000-20,000 cystectomy per patient for initial
candidates
- Ongoing
costs: Surveillance (cystoscopy, imaging) may offset some savings
- Long-term
benefit: Avoided urinary diversion complications reduce lifetime
healthcare utilization
The Bottom Line for Clinicians
- Reframes
cystectomy from obligatory to conditional—for select
patients, surveillance becomes a legitimate alternative
- Demonstrates
that biomarker-driven selection can identify patients with favorable
outcomes off cystectomy
- Provides
evidence supporting patient autonomy in treatment choice
What RETAIN 1 Doesn't Change (Yet):
- The
fundamental role of neoadjuvant chemotherapy (all MIBC patients should
still receive it)
- Cystectomy
remains the standard of care for most MIBC patients
- Trimodal
therapy remains a key bladder-preservation alternative
- Patient
selection remains stringent; ~64% of MIBC patients don't qualify
The Critical Next Step:
- Phase
III randomized trials comparing surveillance versus cystectomy in
comparable populations
- Integration
of quality-of-life outcomes and cost-effectiveness analyses
- Expansion
to diverse populations and cisplatin-ineligible cohorts
